Viridian Therapeutics (Viridian Therapeutics) Tax Rate % : 0.00% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Viridian Therapeutics Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Viridian Therapeutics's Tax Expense for the three months ended in Dec. 2023 was $0.00 Mil. Viridian Therapeutics's Pre-Tax Income for the three months ended in Dec. 2023 was $-66.86 Mil. Therefore, Viridian Therapeutics's Tax Rate % for the quarter that ended in Dec. 2023 was 0.00%.

Viridian Therapeutics Tax Rate % Historical Data

The historical data trend for Viridian Therapeutics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics Tax Rate % Chart

Viridian Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Rate %

Get a 7-Day Free Trial

Viridian Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Tax Rate %	Get a 7-Day Free Trial															-	-	-	-	-

Viridian Therapeutics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Viridian Therapeutics's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %	=	Tax Expense (A: Dec. 2023 )	/	Pre-Tax Income (A: Dec. 2023 )
	=	0	/	-237.734
	=	0.00 %

Viridian Therapeutics's Tax Rate % for the quarter that ended in Dec. 2023 is calculated as

Tax Rate %	=	Tax Expense (Q: Dec. 2023 )	/	Pre-Tax Income (Q: Dec. 2023 )
	=	0	/	-66.86
	=	0.00 %

Viridian Therapeutics Tax Rate % Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Viridian Therapeutics (Viridian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (NAS:VRDN) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

1S1:Germany

Address

221 Crescent Street, Suite 401, Waltham, MA, USA, 02453

Website

https://www.viridiantherapeutics.com

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Executives

Stephen F. Mahoney	director, officer: President and CEO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham	officer: Chief Operating Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sarah Gheuens	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Seth Harmon	officer: See Remarks	C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453
Lara Meisner	officer: General Counsel and Secretary	C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453
Scott Dunseth Myers	director, officer: Chief Executive Officer	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Jonathan Violin	officer: President and COO	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Barrett Katz	officer: Chief Medical Officer	6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301
Fairmount Healthcare Fund Gp Llc	director, other: See Remarks	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Carrie Melvin	officer: COO	C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453
Frazier Life Sciences Public Fund, L.p.	10 percent owner	TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101
L.p. Fhmlsp,	10 percent owner	C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Fhmlsp, L.l.c.	10 percent owner	C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Kristian Humer	officer: CFO and CBO	C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jennifer K. Moses	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709